About Us
- TOP
- Company
Company
| Company Name | iPS Portal, Inc |
|---|---|
| Founded | July 31, 2014 |
| CEO & COO | Masakazu Kobayashi |
| Address | Louis Pasteur Center for Medical Reserch, Bldg., 103-5 Tanaka Monzen-cho , Sakyo-ku, Kyoto 606-8225, Japan |
| Capital | 831 million Yen (capital stock of 99 million Yen, and capital reserve of 732 million Yen) |
| Number of employees | 20 |
Corporate Governance
Director & Auditor
- CEO & COO
Masakazu Kobayashi
- Managing Director CFO
Keiji Nakagawa - CPA
- Managing Director
Yoshio Yamaoka - Professor Emeritus, Kyoto University
- Managing Director
Junya Toguchida - Assistant Director, Center for iPS Research and Application（CiRA）Kyoto University
- Corporate Auditor
Kozo Miseki
- Corporate Auditor
Yoshito Fujikawa - Attorney at Law ,Patent Attorney
Advisory Board
| Scientific Advisory Board | Kenji Osafune, Professor, Center for iPS Cell Research and Application, Kyoto University Kohji Nishida, Professor & Chairman, Department of Ophthalmology, Graduate School of Medicine, Osaka University |
|---|---|
| Management Advisory Board | Motoshige Ito, Emeritus Professor, The University of Tokyo |
| Consultants | Masahiro Kino-oka, Professor, Graduate School of Engineering Osaka University |
| Pharmaceutical Affairs Consultants | Shin Kawamata, Project Professor, Graduate School of Science, Technology and Innovation, Kobe University Zen-ichi Mohri, Regenerative Medicine Advisor for Development |
History
iPS Portal Inc. began operations in September 2014, following the transfer of non-patent related operations of iPS Academia Japan, Inc. At the time of its establishment, iPS Portal Inc. focused on contract testing of iPS cells in efforts to promote the broad use of iPS cell technology. We also provide support for start-up companies related to Cell-Technology, and have been involved in the establishment and operation of Raymei, Inc., a corneal regenerative medicine company since 2016 and Houjou, Inc., a company that aims to protect endangered species and to commercialize fertility treatments since 2020. In January 2021, we moved our headquarters and laboratory to a new location, marking the next stage of our business.We will continue to contribute to the development of the life science field by supporting iPS cells and other Cell-Technology-based research and business from both technology and business perspectives, and by providing higher value-added services.